<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16219105</article-id><article-id pub-id-type="pmc">1266352</article-id><article-id pub-id-type="publisher-id">1471-2407-5-131</article-id><article-id pub-id-type="doi">10.1186/1471-2407-5-131</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Randomized phase II – study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer – PARC: study protocol [ISRCTN56652283]</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Krempien</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>robert_krempien@med.uni-heidelberg.de</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Muenter</surname><given-names>MW</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>marc_muenter@med.uni-heidelberg.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Huber</surname><given-names>PE</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>p.huber@dkfz.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Nill</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>n.siemeon@dkfz.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Friess</surname><given-names>H</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>helmut_friess@med.uni-heidelberg.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Timke</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>carmen_timke@med.uni-heidelberg.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Didinger</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bernd_didinger@med.uni-heidelberg.de</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Buechler</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>peter_buechler@med.uni-heidelberg.de</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Heeger</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>steffen.heeger@merck.de</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Herfarth</surname><given-names>KK</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>klaus_herfarth@med.uni-heidelberg.de</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Abdollahi</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>a.amir@dkfz.de</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Buchler</surname><given-names>MW</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Markus.Buechler@med.uni-heidelberg.de</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Debus</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>juergen_debus@med.uni-heidelberg.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiation Oncology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany</aff><aff id="I2"><label>2</label>Department of Radiation Oncology, German Cancer Research Center (dkfz), 69120 Heidelberg, Germany</aff><aff id="I3"><label>3</label>Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany</aff><aff id="I4"><label>4</label>Department of Medical Physics, German Cancer Research Center (dkfz), 69120 Heidelberg, Germany</aff><aff id="I5"><label>5</label>Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>11</day><month>10</month><year>2005</year></pub-date><volume>5</volume><fpage>131</fpage><lpage>131</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/131"></ext-link><history><date date-type="received"><day>29</day><month>7</month><year>2005</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2005</year></date></history><permissions><copyright-statement>Copyright © 2005 Krempien et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Krempien et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="5508" xml_f="5518" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5529" xml_f="6440" txt_i="22" txt_f="933">Pancreatic cancer is the fourth commonest cause of death from cancer in men and women. Advantages in surgical techniques, radiation therapy techniques, chemotherapeutic regimes, and different combined-modality approaches have yielded only a modest impact on the prognosis of patients with pancreatic cancer. Thus there is clearly a need for additional strategies. One approach involves using the identification of a number of molecular targets that may be responsible for the resistance of cancer cells to radiation or to other cytotoxic agents. As such, these molecular determinants may serve as targets for augmentation of the radiotherapy or chemotherapy response. Of these, the epidermal growth factor receptor (EGFR) has been a molecular target of considerable interest and investigation, and there has been a tremendous surge of interest in pursuing targeted therapy of cancers via inhibition of the EGFR.</offsets></p></sec><sec><title><offsets xml_i="6462" xml_f="6476" txt_i="935" txt_f="949">Methods/design</offsets></title><p><offsets xml_i="6487" xml_f="7415" txt_i="950" txt_f="1878">The PARC study is designed as an open, controlled, prospective, randomized phase II trial. Patients in study arm A will be treated with chemoradiation using intensity modulated radiation therapy (IMRT) combined with gemcitabine and simultaneous cetuximab infusions. After chemoradiation the patients receive gemcitabine infusions weekly over 4 weeks. Patients in study arm B will be treated with chemoradiation using intensity modulated radiation therapy (IMRT) combined with gemcitabine and simultaneous cetuximab infusions. After chemoradiation the patients receive gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks. A total of 66 patients with locally advanced adenocarcinoma of the pancreas will be enrolled. An interim analysis for patient safety reasons will be done one year after start of recruitment. Evaluation of the primary endpoint will be performed two years after the last patient's enrolment.</offsets></p></sec><sec><title><offsets xml_i="7437" xml_f="7447" txt_i="1880" txt_f="1890">Discussion</offsets></title><p><offsets xml_i="7458" xml_f="7881" txt_i="1891" txt_f="2314">The primary objective of this study is to evaluate the feasibility and the toxicity profile of trimodal therapy in pancreatic adenocarcinoma with chemoradiation therapy with gemcitabine and intensity modulated radiation therapy (IMRT) and EGFR-targeted therapy using cetuximab and to compare between two different methods of cetuximab treatment schedules (concomitant versus concomitant and sequential cetuximab treatment).</offsets></p><p><offsets xml_i="7888" xml_f="8200" txt_i="2315" txt_f="2627">Secondary objectives are to determine the role and the mechanism of cetuximab in patient's chemoradiation regimen, the response rate, the potential of this combined modality treatment to concert locally advanced lesions to potentially resectable lesions, the time to progression interval and the quality of life.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="8262" xml_f="8272" txt_i="2636" txt_f="2646">Background</offsets></title><p><offsets xml_i="8283" xml_f="8370" txt_i="2647" txt_f="2734">Pancreatic cancer is the fourth commonest cause of death from cancer in men and women [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8401" xml_f="8402" txt_i="2734" txt_f="2735">1</offsets></xref><offsets xml_i="8409" xml_f="8410" txt_i="2735" txt_f="2736">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8441" xml_f="8442" txt_i="2736" txt_f="2737">2</offsets></xref><offsets xml_i="8449" xml_f="8551" txt_i="2737" txt_f="2839">]. Surgical therapy currently offers the only potential monomodal cure for pancreatic adenocarcinoma [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="8582" xml_f="8583" txt_i="2839" txt_f="2840">3</offsets></xref><offsets xml_i="8590" xml_f="8909" txt_i="2840" txt_f="3159">]. However only a few patients present with tumors that are amenable to resection, end even after resection of localized cancers, long term survival is poor. At presentation, only 20% of patients with pancreatic adenocarcinoma have resectable cancers, 40% have locally advanced tumors, and 40% have metastatic disease [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="8940" xml_f="8941" txt_i="3159" txt_f="3160">5</offsets></xref><offsets xml_i="8948" xml_f="8950" txt_i="3160" txt_f="3162">].</offsets></p><p><offsets xml_i="8957" xml_f="9069" txt_i="3163" txt_f="3275">However, long-term (5-year) survival rates – even for patients undergoing "complete" resection – are below 20% [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="9100" xml_f="9101" txt_i="3275" txt_f="3276">4</offsets></xref><offsets xml_i="9108" xml_f="9109" txt_i="3276" txt_f="3277">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9140" xml_f="9141" txt_i="3277" txt_f="3278">5</offsets></xref><offsets xml_i="9148" xml_f="9423" txt_i="3278" txt_f="3553">]. Loco-regional recurrence and/or metastatic disease develop in the majority of patients who undergo pancreatic resection. Relapse occurs within 9–15 months after initial presentation and patients have median life expectancies of only 12–15 months without adjuvant therapy [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="9454" xml_f="9455" txt_i="3553" txt_f="3554">4</offsets></xref><offsets xml_i="9462" xml_f="9563" txt_i="3554" txt_f="3655">]. The 5-year survival rate of patients with resected pancreatic adenocarinoma is approximately 10% [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9594" xml_f="9595" txt_i="3655" txt_f="3656">6</offsets></xref><offsets xml_i="9602" xml_f="9871" txt_i="3656" txt_f="3925">]. The statistics for the 80 to 90 % of patients who present with locally advanced and metastatic pancreatic cancer are even more dismal. Rarely do such patients achieve a complete response to treatment; median survival is 5–10 months and 5-year survival is near zero [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="9902" xml_f="9903" txt_i="3925" txt_f="3926">7</offsets></xref><offsets xml_i="9910" xml_f="9912" txt_i="3926" txt_f="3928">].</offsets></p><p><offsets xml_i="9919" xml_f="10238" txt_i="3929" txt_f="4248">Both distant and local/regional patterns of recurrence are common, and this suggests that most patients have occult metastatic disease or local/regional (or both) at the time of resection. Postoperative chemoradiationtherapy (CRT) has been shown to improve survival in patients with resected pancreatic adenocarcinoma [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="10269" xml_f="10270" txt_i="4248" txt_f="4249">8</offsets></xref><offsets xml_i="10277" xml_f="10278" txt_i="4249" txt_f="4250">-</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10310" xml_f="10312" txt_i="4250" txt_f="4252">10</offsets></xref><offsets xml_i="10319" xml_f="10400" txt_i="4252" txt_f="4333">], although there is debate over whether radiotherapy is a beneficial component [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="10431" xml_f="10432" txt_i="4333" txt_f="4334">5</offsets></xref><offsets xml_i="10439" xml_f="10440" txt_i="4334" txt_f="4335">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="10472" xml_f="10474" txt_i="4335" txt_f="4337">11</offsets></xref><offsets xml_i="10481" xml_f="10682" txt_i="4337" txt_f="4538">]. The problems with the postoperative adjuvant approach include the fact that at least 25% of patients do not actually receive adjuvant therapy because of complications of surgery or patient refusal [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10714" xml_f="10716" txt_i="4538" txt_f="4540">10</offsets></xref><offsets xml_i="10723" xml_f="10724" txt_i="4540" txt_f="4541">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10756" xml_f="10758" txt_i="4541" txt_f="4543">12</offsets></xref><offsets xml_i="10765" xml_f="11543" txt_i="4543" txt_f="5321">]. A primary advantage of preoperative therapy is therefore the assurance that CRT is received by all patients in a timely fashion. Other benefits are the delivers of radiation to well-oxygenated tissues and the avoidance of radiation to fixed loops of intestine within the operative field. Another rationale for neoadjuvant treatment is that occult metastatic disease is given the opportunity to manifest, thus allowing patients to avoid the morbidity of resection or laparotomy. Finally, the potential for preoperative CRT to convert locally advanced lesions to resectable lesions could greatly increase the number of patients with pancreatic cancer who might be offered a chance of cure. Several trials could show that dose escalation in radiation therapy using either EBRT [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="11574" xml_f="11575" txt_i="5321" txt_f="5322">8</offsets></xref><offsets xml_i="11582" xml_f="11593" txt_i="5322" txt_f="5333">] or IORT [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="11625" xml_f="11627" txt_i="5333" txt_f="5335">13</offsets></xref><offsets xml_i="11634" xml_f="11635" txt_i="5335" txt_f="5336">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="11667" xml_f="11669" txt_i="5336" txt_f="5338">14</offsets></xref><offsets xml_i="11676" xml_f="12000" txt_i="5338" txt_f="5662">] resulted in improved local control in combination with potentially curative resection. The efficacy of external beam irradiation (EBRT) in pancreatic cancer is limited by the inability to deliver adequate doses of irradiation secondary to the dose tolerance limits of small bowel, spinal cord, stomach, kidney, and liver [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="12032" xml_f="12034" txt_i="5662" txt_f="5664">15</offsets></xref><offsets xml_i="12041" xml_f="12170" txt_i="5664" txt_f="5793">]. Further, the use of combined modality approaches in pancreatic cancer is associated with increased gastrointestinal toxicity [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="12202" xml_f="12204" txt_i="5793" txt_f="5795">16</offsets></xref><offsets xml_i="12211" xml_f="12488" txt_i="5795" txt_f="6072">]. Technical developments like intensity-modulated radiation therapy (IMRT) have the potential to significantly improve radiation therapy of pancreatic cancers by reducing normal tissue dose, and simultaneously allow escalation of dose to further enhance locoregional control [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="12520" xml_f="12522" txt_i="6072" txt_f="6074">17</offsets></xref><offsets xml_i="12529" xml_f="12531" txt_i="6074" txt_f="6076">].</offsets></p><p><offsets xml_i="12538" xml_f="12698" txt_i="6077" txt_f="6237">To achieve long-term success in treating this disease it is therefore increasingly important to identify effective neoadjuvant/adjuvant multimodality therapies.</offsets></p><p><offsets xml_i="12705" xml_f="12979" txt_i="6238" txt_f="6512">Concurrent chemoradiation is the standard of care for locally advanced non metastatic pancreatic cancers. Median survival rates vary between different trials depending on their selection criteria between 7 and 12 month, while 1 year overall survival is between 30% and 45% [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="13011" xml_f="13013" txt_i="6512" txt_f="6514">18</offsets></xref><offsets xml_i="13020" xml_f="13022" txt_i="6514" txt_f="6516">].</offsets></p><p><offsets xml_i="13029" xml_f="13178" txt_i="6517" txt_f="6666">Systemic chemotherapy, a mainstay of pancreatic cancer treatment, essentially has been ineffective until recently when gemcitabine became available [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="13210" xml_f="13212" txt_i="6666" txt_f="6668">19</offsets></xref><offsets xml_i="13219" xml_f="13476" txt_i="6668" txt_f="6925">]. In a phase III trial comparing gemcitabine versus 5-flurouracil in advanced pancreatic cancer, patients who received gemcitabine showed a modest improvement in response rate, a marginal survival advantage, and most important, superior clinical response [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="13508" xml_f="13510" txt_i="6925" txt_f="6927">20</offsets></xref><offsets xml_i="13517" xml_f="13737" txt_i="6927" txt_f="7147">]. Therefore gemcitabine became the standard treatment of advanced pancreatic cancer. Despite these results, however median survival duration in patients with advanced pancreatic cancer continues to be less than 6 month.</offsets></p><p><offsets xml_i="13744" xml_f="14576" txt_i="7148" txt_f="7980">Still, advantages in surgical techniques, radiation therapy techniques, chemotherapeutic regimes, and different combined-modality approaches have yielded only a modest impact on the prognosis of patients with pancreatic cancer. Thus there is clearly a need for additional strategies. One approach involves using the identification of a number of molecular targets that may be responsible for the resistance of cancer cells to radiation or to other cytotoxic agents. As such, these molecular determinants may serve as targets for augmentation of the radiotherapy or chemotherapy response. Of these, the epidermal growth factor receptor (EGFR) has been a molecular target of considerable interest and investigation, and there has been a tremendous surge of interest in pursuing targeted therapy of cancers via inhibition of the EGFR [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="14608" xml_f="14610" txt_i="7980" txt_f="7982">21</offsets></xref><offsets xml_i="14617" xml_f="14618" txt_i="7982" txt_f="7983">,</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="14650" xml_f="14652" txt_i="7983" txt_f="7985">22</offsets></xref><offsets xml_i="14659" xml_f="14661" txt_i="7985" txt_f="7987">].</offsets></p><p><offsets xml_i="14668" xml_f="14857" txt_i="7988" txt_f="8177">The overexpression of EGFR has been demonstrated in a number of human tumor types, including head-and-neck cancers, colon cancer, breast cancer, gliomas, lung cancer and pancreatic cancer [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="14889" xml_f="14891" txt_i="8177" txt_f="8179">23</offsets></xref><offsets xml_i="14898" xml_f="14899" txt_i="8179" txt_f="8180">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="14931" xml_f="14933" txt_i="8180" txt_f="8182">24</offsets></xref><offsets xml_i="14940" xml_f="15183" txt_i="8182" txt_f="8425">]. The rationale for investigating of EGFR inhibitors as radiation sensitizers in cancer therapy is based on the following observations: (1) positive correlation between EGFR expression and cellular resistance to radiation in many cell types [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="15215" xml_f="15217" txt_i="8425" txt_f="8427">23</offsets></xref><offsets xml_i="15224" xml_f="15326" txt_i="8427" txt_f="8529">]; (2) the degree of radioresistance correlates positively with the magnitude of EGFR overexpression [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="15358" xml_f="15360" txt_i="8529" txt_f="8531">25</offsets></xref><offsets xml_i="15367" xml_f="15552" txt_i="8531" txt_f="8716">]; (3) cell survival and repopulation during a course of radiotherapy are influenced by activation of EGFR/transforming growth factor alpha that is induced after exposure to radiation [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="15584" xml_f="15586" txt_i="8716" txt_f="8718">26</offsets></xref><offsets xml_i="15593" xml_f="15665" txt_i="8718" txt_f="8790">]; and (4) inhibition of EGFR signaling-enhanced radiation sensitivity [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="15697" xml_f="15699" txt_i="8790" txt_f="8792">27</offsets></xref><offsets xml_i="15706" xml_f="15707" txt_i="8792" txt_f="8793">,</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="15739" xml_f="15741" txt_i="8793" txt_f="8795">28</offsets></xref><offsets xml_i="15748" xml_f="15750" txt_i="8795" txt_f="8797">].</offsets></p><p><offsets xml_i="15757" xml_f="15889" txt_i="8798" txt_f="8930">Cetuximab is a monoclonal antibody that specifically binds to the EGFR, thereby inhibiting downstream signal transduction pathways [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="15921" xml_f="15923" txt_i="8930" txt_f="8932">29</offsets></xref><offsets xml_i="15930" xml_f="16152" txt_i="8932" txt_f="9154">]. It has been shown in vivo and in vitro to enhance radiosensitivity, to promote radiation induced apoptosis, to decrease cell proliferation, to inhibit radiation-induced damage repair, and to inhibit tumor angiogenesis [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="16184" xml_f="16186" txt_i="9154" txt_f="9156">23</offsets></xref><offsets xml_i="16193" xml_f="16195" txt_i="9156" txt_f="9158">].</offsets></p><p><offsets xml_i="16202" xml_f="16494" txt_i="9159" txt_f="9451">Phase I studies have shown that cetuximab has tolerable toxic effects. Acneiform rash is the most common toxic effect. Besides skin toxicity cetuximab has the potential to cause allergic reactions, including anaphylaxis. However, this has not been shown to be a significant clinical problem [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="16526" xml_f="16528" txt_i="9451" txt_f="9453">23</offsets></xref><offsets xml_i="16535" xml_f="16537" txt_i="9453" txt_f="9455">].</offsets></p><p><offsets xml_i="16544" xml_f="16806" txt_i="9456" txt_f="9718">Phase I and II clinical studies on EGFR antibodies given as a single agent were performed in patients with advanced NSCLC, ovarian, head and neck, prostate, and colorectal cancer. Stable disease with tolerable side effects was seen in about 20% of the patients [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="16838" xml_f="16840" txt_i="9718" txt_f="9720">23</offsets></xref><offsets xml_i="16847" xml_f="17181" txt_i="9720" txt_f="10054">]. Several phase I-III trials testing the effect of different EGFR inhibitors combined with radiotherapy or radiochemotherapy are currently ongoing. The so far most important trial testing EGFR inhibition in combination with radiotherapy was a randomized phase III trial testing radiotherapy alone versus radiotherapy plus cetuximab [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="17213" xml_f="17215" txt_i="10054" txt_f="10056">30</offsets></xref><offsets xml_i="17222" xml_f="17430" txt_i="10056" txt_f="10264">]. 424 patients with loco-regionally advanced squamous cell carcinoma or head-and-neck cancers were randomized into curative radiotherapy plus/minus cetuximab. Cetuximab was applied once at a dose of 400 mg/m</offsets><sup><offsets xml_i="17435" xml_f="17437" txt_i="10264" txt_f="10266">2 </offsets></sup><offsets xml_i="17443" xml_f="17551" txt_i="10266" txt_f="10374">in the week prior to radiotherapy (week1) and weekly during the course of radiotherapy at a dose of 250 mg/m</offsets><sup><offsets xml_i="17556" xml_f="17558" txt_i="10374" txt_f="10376">2 </offsets></sup><offsets xml_i="17564" xml_f="18037" txt_i="10376" txt_f="10849">before irradiation. Locoregional tumor control rates after 1 and 2 years were 69% and 56% for patients treated simultaneously with cetuximab versus 59% and 48% for patients who received radiotherapy alone (p = 0.02). Overall survival rates at 2 and 3 years after treatment were 62% and 57% for cetuximab treated patients and 55% and 44% for patients with irradiation alone (p = 0.02). Median survival times were 54 months (95%C.I.36;58) and 28 months (21;38), respectively.</offsets></p><p><offsets xml_i="18044" xml_f="18196" txt_i="10850" txt_f="11002">A recently completed phase II trial of cetuximab in combination with gemcitabine for patients with advanced pancreatic cancer showed promising results [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="18228" xml_f="18230" txt_i="11002" txt_f="11004">31</offsets></xref><offsets xml_i="18237" xml_f="18918" txt_i="11004" txt_f="11685">]. In that trial 41 patients received cetuximab with gemcitabine and were evaluated for efficacy and toxicity. The toxicity profile of this combination was consistent with that of gemcitabine, except for acneiforme rash induced by cetuximab. A partial response rate of 12.2% (5 patients) and stable disease rate of 63.4% was observed in this study. Medial time to progression and medial survival duration were 3.8 months and 7.1 months, respectively, while 1-year survival rates and progression-free survival rates were 31.7% and 12%, respectively. This 1-year survival is considerably better than that achieved using gemcitabine alone as documented in a previous phase III trial [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="18950" xml_f="18952" txt_i="11685" txt_f="11687">20</offsets></xref><offsets xml_i="18959" xml_f="19132" txt_i="11687" txt_f="11860">]. Recently a phase three study could demonstrate the benefit of the combination of an EGFR tyrosine kinase inhibitor in combination with chemotherapy in pancreatic cancer [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="19164" xml_f="19166" txt_i="11860" txt_f="11862">32</offsets></xref><offsets xml_i="19173" xml_f="19646" txt_i="11862" txt_f="12335">]. A total of 569 patients with advanced pancreatic cancer were randomized to receive standard dose gemcitabine, 1000 mg/m2 iv weekly in 7 out of 8 weeks, than weekly 3 out of four weeks plus either erlotininb 100 mg daily (n = 285) or placebo (n = 284). Combined erlotinib therapy with gemcintabine resulted in a 24% improvment in survival as compared to placebo (p = 0.025) with corresponding 1-year survival rate of 24% and 17% (erlotinib and placebo arm, respectively).</offsets></p><p><offsets xml_i="19653" xml_f="20212" txt_i="12336" txt_f="12895">Regarding the benefits of EGFR-targeted therapy in the combined modality treatment using either irradiation or chemotherapy, it is increasingly becoming clear that EGFR-targeted therapy is an important novel strategy for the treatment of pancreatic cancers. Since chemoradiation is the standard of care for locally advanced non metastatic pancreatic cancer, there has been considerable interest in gaining increased experience with this therapy in combination with chemoradiation in an effort to evaluate the efficacy and the toxicity profile of this regimen.</offsets></p></sec><sec><title><offsets xml_i="20234" xml_f="20248" txt_i="12897" txt_f="12911">Methods/design</offsets></title><sec><title><offsets xml_i="20268" xml_f="20286" txt_i="12912" txt_f="12930">Trial organization</offsets></title><p><offsets xml_i="20297" xml_f="20675" txt_i="12931" txt_f="13309">PARC has been designed by the Trial Center of the Department of Radiation Oncology, University of Heidelberg. The trial is carried out by the Department of Radiation Oncology together with the German Cancer Research Center (DKFZ) and Department of Surgery. The trial is an investigator initiated trial. Trial medication (cetuximab) is supplied by Merck KGaA, Darmstadt, Germany.</offsets></p></sec><sec><title><offsets xml_i="20697" xml_f="20709" txt_i="13311" txt_f="13323">Coordination</offsets></title><p><offsets xml_i="20720" xml_f="21052" txt_i="13324" txt_f="13656">The trial is co-ordinated by the Department of Radiation Oncology in cooperation with the DKFZ and the Department of Surgery at the University of Heidelberg. The Dept. of Radiation Oncology is responsible for overall trial management, trial registration (International Standard Randomized Controlled Trial Number [ISRCTN 56652283], </offsets><ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com"></ext-link><offsets xml_i="21139" xml_f="21275" txt_i="13656" txt_f="13792">), database management, quality assurance including monitoring, reporting and for the scientific program of all trial related meetings).</offsets></p></sec><sec><title><offsets xml_i="21297" xml_f="21310" txt_i="13794" txt_f="13807">Investigators</offsets></title><p><offsets xml_i="21321" xml_f="21650" txt_i="13808" txt_f="14137">Patients will be recruited by the Department of Radiation Oncology at the University of Heidelberg. Due to the multi-modal nature of the trial, all investigators are experienced oncologists from the fields of radiation oncology, hematology/oncology, and general surgery at the University of Heidelberg co-operating in this trial.</offsets></p></sec><sec><title><offsets xml_i="21672" xml_f="21696" txt_i="14139" txt_f="14163">Adverse events committee</offsets></title><p><offsets xml_i="21707" xml_f="22102" txt_i="14164" txt_f="14559">This committee consists of 3 independent physicians (medical oncologist, radiation oncologist and surgeon) and decides on the final diagnostic classification of critical clinical events. For all serious adverse events the documentation and relevant patient data are verified by the co-ordinating personnel before submitting the data to the Adverse Events Committee for diagnostic classification.</offsets></p><p><offsets xml_i="22109" xml_f="22183" txt_i="14560" txt_f="14634">Analysis of safety related data is performed with respect to frequency of:</offsets></p><p><offsets xml_i="22190" xml_f="22260" txt_i="14635" txt_f="14705">• Serious Adverse Events and Adverse Events stratified by organ-system</offsets></p><p><offsets xml_i="22267" xml_f="22306" txt_i="14706" txt_f="14745">• Adverse Events stratified by severity</offsets></p><p><offsets xml_i="22313" xml_f="22354" txt_i="14746" txt_f="14787">• Adverse Events stratified by causality.</offsets></p><p><offsets xml_i="22361" xml_f="22972" txt_i="14788" txt_f="15399">Patient toxicities will be assessed using the NCI Common Toxicity Criteria (CTC). Toxicity will be evaluated pretreatment, weekly during chemoradiation /chemotherapy, prior to each course of infusional Cetuximab and at follow-up. Unacceptable toxicity is defined as unpredictable, or irreversible Grade 4 toxicity. Decisions regarding weekly chemoradiation treatment, chemotherapy dose-adjustment, and cetuximab dose-adjustment will be made using the guidelines below and based on hematological parameters (ANC and platelets) monitored weekly during chemoradiation before each dose of cetuximab and gemcitabine.</offsets></p></sec><sec><title><offsets xml_i="22994" xml_f="23011" txt_i="15401" txt_f="15418">Medication supply</offsets></title><p><offsets xml_i="23022" xml_f="23389" txt_i="15419" txt_f="15786">All chemotherapeutic agents are prepared and provided by the pharmacy of the University Hospital Heidelberg. Cetuximab is provided by Merck KGaA, Darmstadt, and is stored by the pharmacy of the University Hospital Heidelberg. Medication will be prepared for each patient specifically and delivered just prior to administration to the Department of Radiation Oncology.</offsets></p></sec><sec><title><offsets xml_i="23411" xml_f="23429" txt_i="15788" txt_f="15806">On-site monitoring</offsets></title><p><offsets xml_i="23440" xml_f="23787" txt_i="15807" txt_f="16154">During recruitment of patients monitoring on site is performed according to good clinical practice (GCP) guidelines. The data management will be performed by the Trial Center of the Department of Radiation Oncology, University of Heidelberg. The medical monitoring will be done by two independent oncologists not involved in conducting this trial.</offsets></p></sec><sec><title><offsets xml_i="23809" xml_f="23844" txt_i="16156" txt_f="16191">Ethics, informed consent and safety</offsets></title><p><offsets xml_i="23855" xml_f="23972" txt_i="16192" txt_f="16309">The final protocol was approved by the ethics committee of the University of Heidelberg, Medical School (L-283/2004, </offsets><ext-link ext-link-type="uri" xlink:href="http://www.klinikum.uni-heidelberg.de/"></ext-link><offsets xml_i="24065" xml_f="24521" txt_i="16309" txt_f="16765"> Paul-Ehrlich-Institute (PEI) registration number 1205/01). This study complies with the Helsinki Declaration in its recent German version, the Medical Association's professional code of conduct, the principles of Good Clinical Practice (GCP) guidelines and the Federal Data Protection Act. The trial will also be carried out in keeping with local legal and regulatory requirements. The medical secrecy and the Federal Data Protection Act will be followed.</offsets></p><p><offsets xml_i="24528" xml_f="24873" txt_i="16766" txt_f="17111">Written informed consent is obtained from each patient in oral and written form before inclusion in the trial and the nature, scope, and possible consequences of the trial have been explained by a physician. The investigator will not undertake any measures specifically required only for the clinical trial until valid consent has been obtained.</offsets></p></sec><sec><title><offsets xml_i="24895" xml_f="24912" txt_i="17113" txt_f="17130">Patient selection</offsets></title><p><offsets xml_i="24923" xml_f="25306" txt_i="17131" txt_f="17514">PARC focuses on hospitalized patients over 18 years of age treated with pancreatic head resection for pancreatic adenocarcinoma during an 18-months period started in August 2004. Men and women over eighteen years of age with locally advanced pancreatic adenocarcinoma will be screened for participation in the study. A detailed overview of all eligibility criteria is given in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="25338" xml_f="25339" txt_i="17514" txt_f="17515">2</offsets></xref><offsets xml_i="25346" xml_f="25347" txt_i="17515" txt_f="17516">.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="25395" xml_f="25402" txt_i="17517" txt_f="17524">Table 2</offsets></label><caption><p><offsets xml_i="25422" xml_f="25442" txt_i="17524" txt_f="17544">Eligibility Criteria</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold><offsets xml_i="25529" xml_f="25547" txt_i="17545" txt_f="17563">Inclusion criteria</offsets></bold></td><td align="center"><bold><offsets xml_i="25584" xml_f="25602" txt_i="17564" txt_f="17582">Exclusion criteria</offsets></bold></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="25655" xml_f="25691" txt_i="17583" txt_f="17619">• Age equal or greater than 18 years</offsets><break></break><offsets xml_i="25706" xml_f="25769" txt_i="17619" txt_f="17682">• Primary inoperable locally advanced pancreatic adenocarcinoma</offsets><break></break><offsets xml_i="25784" xml_f="25820" txt_i="17682" txt_f="17718">• No evidence of metastatic disease.</offsets><break></break><offsets xml_i="25835" xml_f="25876" txt_i="17718" txt_f="17753">• Hb &gt;10.0 g/%, WBC &gt;3,000 cells/mm</offsets><sup><offsets xml_i="25881" xml_f="25882" txt_i="17753" txt_f="17754">3</offsets></sup><offsets xml_i="25888" xml_f="25920" txt_i="17754" txt_f="17783">, platelets &gt;100,000 cells/mm</offsets><sup><offsets xml_i="25925" xml_f="25926" txt_i="17783" txt_f="17784">3</offsets></sup><offsets xml_i="25932" xml_f="25933" txt_i="17784" txt_f="17785">.</offsets><break></break><offsets xml_i="25948" xml_f="25984" txt_i="17785" txt_f="17821">• Performance status: Karnofsky ≥70.</offsets><break></break><offsets xml_i="25999" xml_f="26055" txt_i="17821" txt_f="17877">• No acute infections at the time of therapy initiation.</offsets><break></break><offsets xml_i="26070" xml_f="26117" txt_i="17877" txt_f="17924">• Patient must be able to give informed consent</offsets><break></break><offsets xml_i="26132" xml_f="26168" txt_i="17924" txt_f="17960">• Patient has given informed consent</offsets></td><td align="left"><offsets xml_i="26190" xml_f="26208" txt_i="17961" txt_f="17979">• Active infection</offsets><break></break><offsets xml_i="26223" xml_f="26250" txt_i="17979" txt_f="18006">• Liver function impairment</offsets><break></break><offsets xml_i="26265" xml_f="26294" txt_i="18006" txt_f="18035">• Pregnancy or breastfeeding.</offsets><break></break><offsets xml_i="26309" xml_f="26329" txt_i="18035" txt_f="18055">• Metastatic disease</offsets><break></break><offsets xml_i="26344" xml_f="26375" txt_i="18055" txt_f="18086">• Other severe systemic disease</offsets><break></break><offsets xml_i="26390" xml_f="26525" txt_i="18086" txt_f="18221">• Second malignancy (except carcinoma in situ of the cervix uteri, basal cell carcinoma of the skin after adequate oncologic treatment)</offsets><break></break><offsets xml_i="26540" xml_f="26605" txt_i="18221" txt_f="18286">• Any other experimental treatment 4 weeks before study inclusion</offsets><break></break><offsets xml_i="26620" xml_f="26671" txt_i="18286" txt_f="18337">• Known positive HACA (human antichimeric antibody)</offsets><break></break><offsets xml_i="26686" xml_f="26730" txt_i="18337" txt_f="18381">• Known allergy against extrinsical proteins</offsets><break></break><offsets xml_i="26745" xml_f="26772" txt_i="18381" txt_f="18408">• Previous antibody therapy</offsets><break></break><offsets xml_i="26787" xml_f="26837" txt_i="18408" txt_f="18458">• Allergy against iv contrast agent (for CT-scans)</offsets><break></break><offsets xml_i="26852" xml_f="26944" txt_i="18458" txt_f="18550">• Previous chemo- and/or radiation treatment or EGFR-inhibitor therapy for pancreatic cancer</offsets><break></break><offsets xml_i="26959" xml_f="26979" txt_i="18550" txt_f="18570">• Lack of compliance</offsets><break></break><offsets xml_i="26994" xml_f="27146" txt_i="18570" txt_f="18722">• Inability to follow the instructions given by the investigator or the telephone interviewer (insufficient command of language, dementia, lack of time)</offsets><break></break><offsets xml_i="27161" xml_f="27187" txt_i="18722" txt_f="18748">• Lack of informed consent</offsets></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="27244" xml_f="27256" txt_i="18750" txt_f="18762">Study design</offsets></title><p><offsets xml_i="27267" xml_f="27821" txt_i="18763" txt_f="19317">The PARC study is designed as an open, controlled, prospective, randomized feasibility phase II trial meant to evaluate the efficacy and toxicity of chemoradiation in combination with cetuximab for patients with locally advanced pancreatic cancer. Compared are chemoradiation with simultaneous cetuximab versus chemoradiation with simultaneous/sequential cetuximab. The treatment is offered to a heterogeneous group of people under clinical circumstances, covering a wide age range, for both sexes and with heterogeneous characteristics / co-morbidities.</offsets></p><p><offsets xml_i="27828" xml_f="27993" txt_i="19318" txt_f="19483">One year after inclusion of the first patient an interim analysis will be performed. The study design will not be changed prior to agreement of the ethics committee.</offsets></p></sec><sec><title><offsets xml_i="28015" xml_f="28031" txt_i="19485" txt_f="19501">Study objectives</offsets></title><p><offsets xml_i="28042" xml_f="28384" txt_i="19502" txt_f="19844">The primary objective is to evaluate the feasibility and the toxicity profile of this regimen and to compare between two different methods of cetuximab treatment schedules (concomitant versus concomitant and sequential cetuximab treatment) in combination with chemoradiation therapy with gemcitabine and intensity modulated radiation therapy.</offsets></p><p><offsets xml_i="28391" xml_f="28703" txt_i="19845" txt_f="20157">Secondary objectives are to determine the role and the mechanism of cetuximab in patient's chemoradiation regimen, the response rate, the potential of this combined modality treatment to concert locally advanced lesions to potentially resectable lesions, the time to progression interval and the quality of life.</offsets></p></sec><sec><title><offsets xml_i="28725" xml_f="28772" txt_i="20159" txt_f="20206">Randomization and standardized treatment scheme</offsets></title><p><offsets xml_i="28783" xml_f="29209" txt_i="20207" txt_f="20633">A block-randomization-list is generated via computer system (SAS Version 8.2, SAS Institute Inc., Cary, USA). The sealed randomization list is stored in the investigator file. Patients are randomized using sealed opaque envelopes in the independent study center at the Department of radiation oncology until informed consent is attained and diagnostic procedures rule out any contra-indication for participation in this trial.</offsets></p><p><offsets xml_i="29216" xml_f="29301" txt_i="20634" txt_f="20719">After randomization and pre-treatment evaluation treatment must begin within 2 weeks.</offsets></p><p><offsets xml_i="29308" xml_f="29407" txt_i="20720" txt_f="20819">All patients will receive a combination with radiotherapy, gemcitabine weekly and cetuximab weekly.</offsets></p><sec><title><offsets xml_i="29423" xml_f="29434" txt_i="20820" txt_f="20831">Study arm A</offsets></title><p><offsets xml_i="29445" xml_f="29493" txt_i="20832" txt_f="20880">Cetuximab will be given as loading dose 400 mg/m</offsets><sup><offsets xml_i="29498" xml_f="29500" txt_i="20880" txt_f="20882">2 </offsets></sup><offsets xml_i="29506" xml_f="29583" txt_i="20882" txt_f="20959">over 120 minutes on day 1. On day 8,15,22,29, 36 (5 doses) cetuximab 250 mg/m</offsets><sup><offsets xml_i="29588" xml_f="29590" txt_i="20959" txt_f="20961">2 </offsets></sup><offsets xml_i="29596" xml_f="29739" txt_i="20961" txt_f="21104">over 60 minutes will be given simultaneously with radiation. Non-steroidal anti-inflammatory drugs and steroids will be given before cetuximab.</offsets></p><p><offsets xml_i="29746" xml_f="29766" txt_i="21105" txt_f="21125">Gemcitabine 300 mg/m</offsets><sup><offsets xml_i="29771" xml_f="29773" txt_i="21125" txt_f="21127">2 </offsets></sup><offsets xml_i="29779" xml_f="29931" txt_i="21127" txt_f="21279">over 60 minutes will be given on day 12,19,26,33,40 (5 doses) 2 hours after radiation therapy. Sequential chemotherapy with gemcitabine weekly 1000 mg/m</offsets><sup><offsets xml_i="29936" xml_f="29938" txt_i="21279" txt_f="21281">2 </offsets></sup><offsets xml_i="29944" xml_f="30116" txt_i="21281" txt_f="21453">over 60 minutes will be continued after finishing radiotherapy on day 47, 54, 62. The timing of these courses will be adjusted in patients who have treatment interruptions.</offsets></p><p><offsets xml_i="30123" xml_f="30966" txt_i="21454" txt_f="22297">External beam radiation is to be given concurrently with chemotherapy and cetuximab with a total dose of 54 Gy in 25 fractions over 5 weeks. Patients are to be treated using an integrated intensity modulated radiation therapy (IMRT) boost concept, which allows the use of different single doses for the gross target volume (GTV) and the clinical target volume (CTV) in one fraction. GTV includes only the gross tumor volume, whereas CTV includes the primary tumor and the regional lymphnodes including the hepatoduodenal ligament, origins of the celiac axis and superior mesenteric artery. The median total dose for the GTV is to be 54.0 Gy (single dose 2.16 Gy) and for the CTV 45.0 Gy (single dose 1.8 Gy). The dose constraints for stomach, duodenum, small intestine, colon are 45 Gy in the maximum, mean dose for kidneys should be below 10 </offsets></p></sec><sec><title><offsets xml_i="30988" xml_f="30999" txt_i="22299" txt_f="22310">Study arm B</offsets></title><p><offsets xml_i="31010" xml_f="31059" txt_i="22311" txt_f="22360">Cetuximab will be given as loading dose 400 mg/ m</offsets><sup><offsets xml_i="31064" xml_f="31066" txt_i="22360" txt_f="22362">2 </offsets></sup><offsets xml_i="31072" xml_f="31148" txt_i="22362" txt_f="22438">over 60 minutes on day 1. On day 8,15,22,29, 36 (5 doses) cetuximab 250 mg/m</offsets><sup><offsets xml_i="31153" xml_f="31155" txt_i="22438" txt_f="22440">2 </offsets></sup><offsets xml_i="31161" xml_f="31304" txt_i="22440" txt_f="22583">over 60 minutes will be given simultaneously with radiation. Non-steroidal anti-inflammatory drugs and steroids will be given before cetuximab.</offsets></p><p><offsets xml_i="31311" xml_f="31341" txt_i="22584" txt_f="22614">Sequential cetuximab 250 mg/ m</offsets><sup><offsets xml_i="31346" xml_f="31348" txt_i="22614" txt_f="22616">2 </offsets></sup><offsets xml_i="31354" xml_f="31435" txt_i="22616" txt_f="22697">over 60 minutes will be given weekly beginning on day 46, over 3 month (12 doses)</offsets></p><p><offsets xml_i="31442" xml_f="31486" txt_i="22698" txt_f="22742">Gemcitabine will be given as in study arm A.</offsets></p><p><offsets xml_i="31493" xml_f="31549" txt_i="22743" txt_f="22799">External beam radiation will be given as in study arm A.</offsets></p><p><offsets xml_i="31556" xml_f="31705" txt_i="22800" txt_f="22949">Restaging using computed tomography will be performed 5 weeks after completion of radiotherapy and at the end of sequential cetuximab administration.</offsets></p><p><offsets xml_i="31712" xml_f="31757" txt_i="22950" txt_f="22995">The treatment protocol is outlined in figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="31787" xml_f="31788" txt_i="22995" txt_f="22996">1</offsets></xref><offsets xml_i="31795" xml_f="31796" txt_i="22996" txt_f="22997">.</offsets></p><fig position="float" id="F1"><label><offsets xml_i="31837" xml_f="31845" txt_i="22998" txt_f="23006">Figure 1</offsets></label><caption><p><offsets xml_i="31865" xml_f="31887" txt_i="23006" txt_f="23028">PARC treatment scheme.</offsets></p></caption><graphic xlink:href="1471-2407-5-131-1"></graphic></fig></sec></sec><sec><title><offsets xml_i="31981" xml_f="32017" txt_i="23031" txt_f="23067">Investigation schedule and follow-up</offsets></title><p><offsets xml_i="32028" xml_f="32301" txt_i="23068" txt_f="23341">All patients (study arm A or B) must have appropriate lab and radiographic studies (CXR; bone scintigraphy, abdominal ultrasound, CT abdomen; CBC; platelet count; BUN; creatinine; bilirubin, CA 19-9, and CEA) conducted prior to study enrolment to meet eligibility criteria.</offsets></p><p><offsets xml_i="32308" xml_f="32620" txt_i="23342" txt_f="23654">During days 1–70 [study arm A] or days 1–130 [study arm B] patients will be assessed with laboratory evaluation: complete blood count and blood chemistries weekly. Laboratory parameters in both study arms will be evaluated before each dose of gemcitabine, in study arm B during cetuximab weekly before cetuximab.</offsets></p><p><offsets xml_i="32627" xml_f="33128" txt_i="23655" txt_f="24156">Vital signs (blood pressure and pulse rate) and temperature are controlled daily during treatment. Patients are evaluated prior to receiving chemoradiation or chemotherapy. Patients enrolled in study arm A and B are evaluated weekly by the radiation oncology team during treatment. The team will check patients at each visit for symptoms due to therapy; a physical examination and complete safety labs should be performed. The quality of life questionnaire will be filled out during weeks 1, 9 and 17.</offsets></p><p><offsets xml_i="33135" xml_f="33391" txt_i="24157" txt_f="24413">During post-chemoradiation, infusional cetuximab weekly (Study Arm B) patients will be evaluated by a physician prior to treatment and every 2 to 3 weeks with clinical assessment and laboratory parameters including a CBC, electrolytes, BUN, and creatinine.</offsets></p><p><offsets xml_i="33398" xml_f="33622" txt_i="24414" txt_f="24638">In the post-treatment period patients will be seen every 3 months by the radiation oncology department for the first 2 years, every 4 months for the third year, and every 6 months during the 4th and 5th post-treatment years.</offsets></p><p><offsets xml_i="33629" xml_f="33801" txt_i="24639" txt_f="24811">The aggregate clinical, laboratory, and imaging evaluations required per protocol as well as the timing of the optional quality of life questionnaire are outlined in table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="33833" xml_f="33834" txt_i="24811" txt_f="24812">1</offsets></xref><offsets xml_i="33841" xml_f="33842" txt_i="24812" txt_f="24813">.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="33890" xml_f="33897" txt_i="24814" txt_f="24821">Table 1</offsets></label><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><offsets xml_i="33976" xml_f="33989" txt_i="24821" txt_f="24834">Investigation</offsets></bold></td><td align="center"><bold><offsets xml_i="34026" xml_f="34038" txt_i="24835" txt_f="24847">Pretreatment</offsets></bold></td><td align="center"><bold><offsets xml_i="34075" xml_f="34111" txt_i="24848" txt_f="24884">Chemoradiation / Chemotherapy weekly</offsets></bold></td><td align="center"><bold><offsets xml_i="34148" xml_f="34196" txt_i="24885" txt_f="24933">Each Course of Infusional Gemcitabine/ Cetuximab</offsets></bold></td><td align="center"><bold><offsets xml_i="34233" xml_f="34242" txt_i="24934" txt_f="24943">follow-up</offsets></bold></td></tr></thead><tbody><tr><td align="left"><bold><offsets xml_i="34301" xml_f="34321" txt_i="24944" txt_f="24964">Clinical examination</offsets></bold></td><td align="center"><offsets xml_i="34352" xml_f="34353" txt_i="24965" txt_f="24966">X</offsets></td><td align="center"><offsets xml_i="34377" xml_f="34378" txt_i="24967" txt_f="24968">X</offsets></td><td align="center"><offsets xml_i="34402" xml_f="34403" txt_i="24969" txt_f="24970">X</offsets></td><td align="center"><offsets xml_i="34427" xml_f="34428" txt_i="24971" txt_f="24972">X</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="34465" xml_f="34481" txt_i="24973" txt_f="24989">Laboratory tests</offsets></bold></td><td align="center"><offsets xml_i="34512" xml_f="34513" txt_i="24990" txt_f="24991">X</offsets><sup><offsets xml_i="34518" xml_f="34519" txt_i="24991" txt_f="24992">a</offsets></sup></td><td align="center"><offsets xml_i="34549" xml_f="34550" txt_i="24993" txt_f="24994">X</offsets></td><td align="center"><offsets xml_i="34574" xml_f="34575" txt_i="24995" txt_f="24996">X</offsets></td><td align="center"><offsets xml_i="34599" xml_f="34600" txt_i="24997" txt_f="24998">X</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="34637" xml_f="34650" txt_i="24999" txt_f="25012">Tumor markers</offsets></bold></td><td align="center"><offsets xml_i="34681" xml_f="34682" txt_i="25013" txt_f="25014">X</offsets><sup><offsets xml_i="34687" xml_f="34688" txt_i="25014" txt_f="25015">b</offsets></sup></td><td align="center"><offsets xml_i="34718" xml_f="34719" txt_i="25016" txt_f="25017">X</offsets></td><td align="center"><offsets xml_i="34743" xml_f="34744" txt_i="25018" txt_f="25019">X</offsets></td><td align="center"><offsets xml_i="34768" xml_f="34769" txt_i="25020" txt_f="25021">X</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="34806" xml_f="34816" txt_i="25022" txt_f="25032">CT Abdomen</offsets></bold></td><td align="center"><offsets xml_i="34847" xml_f="34848" txt_i="25033" txt_f="25034">X</offsets></td><td></td><td></td><td align="center"><offsets xml_i="34890" xml_f="34891" txt_i="25037" txt_f="25038">X</offsets><sup><italic><offsets xml_i="34904" xml_f="34905" txt_i="25038" txt_f="25039">c</offsets></italic></sup></td></tr><tr><td align="left"><bold><offsets xml_i="34957" xml_f="34969" txt_i="25040" txt_f="25052">CXR, PA, LAT</offsets></bold></td><td align="center"><offsets xml_i="35000" xml_f="35001" txt_i="25053" txt_f="25054">X</offsets></td><td></td><td align="center"><offsets xml_i="35034" xml_f="35035" txt_i="25056" txt_f="25057">X</offsets></td><td align="center"><offsets xml_i="35059" xml_f="35060" txt_i="25058" txt_f="25059">X</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="35097" xml_f="35111" txt_i="25060" txt_f="25074">Renal function</offsets></bold></td><td align="center"><offsets xml_i="35142" xml_f="35143" txt_i="25075" txt_f="25076">X</offsets><sup><italic><offsets xml_i="35156" xml_f="35157" txt_i="25076" txt_f="25077">d</offsets></italic></sup></td><td></td><td></td><td></td></tr><tr><td align="left"><bold><offsets xml_i="35236" xml_f="35250" txt_i="25081" txt_f="25095">Pregnancy Test</offsets></bold><sup><offsets xml_i="35262" xml_f="35263" txt_i="25095" txt_f="25096">f</offsets></sup></td><td align="center"><offsets xml_i="35293" xml_f="35294" txt_i="25097" txt_f="25098">X</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><bold><offsets xml_i="35358" xml_f="35361" txt_i="25102" txt_f="25105">SAE</offsets></bold></td><td align="center"><offsets xml_i="35392" xml_f="35393" txt_i="25106" txt_f="25107">X</offsets></td><td align="center"><offsets xml_i="35417" xml_f="35418" txt_i="25108" txt_f="25109">X</offsets></td><td align="center"><offsets xml_i="35442" xml_f="35443" txt_i="25110" txt_f="25111">X</offsets></td><td></td></tr><tr><td align="left"><bold><offsets xml_i="35489" xml_f="35499" txt_i="25113" txt_f="25123">QOL Survey</offsets></bold></td><td align="center"><offsets xml_i="35530" xml_f="35531" txt_i="25124" txt_f="25125">X</offsets><sup><italic><offsets xml_i="35544" xml_f="35545" txt_i="25125" txt_f="25126">e</offsets></italic></sup></td><td align="center"><offsets xml_i="35584" xml_f="35585" txt_i="25127" txt_f="25128">X</offsets></td><td align="center"><offsets xml_i="35609" xml_f="35610" txt_i="25129" txt_f="25130">X</offsets></td><td align="center"><offsets xml_i="35634" xml_f="35635" txt_i="25131" txt_f="25132">X</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="35681" xml_f="35799" txt_i="25133" txt_f="25251">a. Includes Electrolytes, BUN, Creatinine, SGOT, Alk Phos, Total Bilirubin, Albumin, Glucose, Calcium, auto-antibodies</offsets></p><p><offsets xml_i="35806" xml_f="35833" txt_i="25252" txt_f="25279">b. Includes CEA and CA 19-9</offsets></p><p><offsets xml_i="35840" xml_f="35924" txt_i="25280" txt_f="25364">c. A CT scan will be performed 4 weeks after chemoradiation and than every 3 months.</offsets></p><p><offsets xml_i="35931" xml_f="35964" txt_i="25365" txt_f="25398">d. Includes CT with i.v. contrast</offsets></p><p><offsets xml_i="35971" xml_f="35993" txt_i="25399" txt_f="25421">e. QLQ-C30, QLQ-Pan 26</offsets></p><p><offsets xml_i="36000" xml_f="36015" txt_i="25422" txt_f="25437">f. If indicated</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="36053" xml_f="36162" txt_i="25438" txt_f="25547">The follow-up will be continued for two years. Follow-up data of overall survival will be evaluated annually.</offsets></p></sec><sec><title><offsets xml_i="36184" xml_f="36213" txt_i="25549" txt_f="25578">Assessment of quality of life</offsets></title><p><offsets xml_i="36224" xml_f="36526" txt_i="25579" txt_f="25881">Measurement of quality of life is one of the secondary objectives of the trial. Overall survival, return to previous employment as well as persistence of symptoms, the ability to perform appropriate activities and to care for oneself are criteria applied in the three questionnaires used in this study.</offsets></p><p><offsets xml_i="36533" xml_f="36833" txt_i="25882" txt_f="26182">EORTC QLQ-C30 is a general measure of qualitiy of life in cancer patients. It incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality-of-life scale [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="36865" xml_f="36867" txt_i="26182" txt_f="26184">33</offsets></xref><offsets xml_i="36874" xml_f="37345" txt_i="26184" txt_f="26652">]. Specific symptoms (dyspnoea, insomnia, anorexia, constipation, diarrhoea, and financial impact) are measured as six single items. This instrument has been used extensively with a variety of cancer patients and was able to discriminate between individuals with metastatic and non-metastatic disease, as well as between patients at different stages of illness. The scale has good internal consistency (alpha &gt; 0.70), and good test re-test reliability (0.80 to 0.90) [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="37377" xml_f="37379" txt_i="26652" txt_f="26654">34</offsets></xref><offsets xml_i="37386" xml_f="37388" txt_i="26654" txt_f="26656">].</offsets></p><p><offsets xml_i="37395" xml_f="37511" txt_i="26657" txt_f="26773">To assess disease-specific symptoms for patients with pancreatic cancer the pancreatic specific module (QLQ-PAN26) [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="37543" xml_f="37545" txt_i="26773" txt_f="26775">35</offsets></xref><offsets xml_i="37552" xml_f="37636" txt_i="26775" txt_f="26859">] that has been designed to use long with the general measure is used in this study.</offsets></p></sec><sec><title><offsets xml_i="37658" xml_f="37693" txt_i="26861" txt_f="26896">Evaluation of the role of cetuximab</offsets></title><p><offsets xml_i="37704" xml_f="38008" txt_i="26897" txt_f="27201">An investigation of the effects and mechanism of cetuximab will be performed. Cetuximab has been shown in vivo and in vitro to enhance radiosensitivity, to promote radiation induced apoptosis, to decrease cell proliferation, to inhibit radiation-induced damage repair, and to inhibit tumor angiogenesis [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="38040" xml_f="38042" txt_i="27201" txt_f="27203">23</offsets></xref><offsets xml_i="38049" xml_f="38050" txt_i="27203" txt_f="27204">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="38082" xml_f="38084" txt_i="27204" txt_f="27206">24</offsets></xref><offsets xml_i="38091" xml_f="38092" txt_i="27206" txt_f="27207">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="38124" xml_f="38126" txt_i="27207" txt_f="27209">36</offsets></xref><offsets xml_i="38133" xml_f="38345" txt_i="27209" txt_f="27421">]. In view of the encouraging results achieved by using cetuximab in combination with other antineoplastic therapies, studies are now needed to define the molecular and immunologic mechanism(s) of this modality [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="38377" xml_f="38379" txt_i="27421" txt_f="27423">30</offsets></xref><offsets xml_i="38386" xml_f="38387" txt_i="27423" txt_f="27424">,</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="38419" xml_f="38421" txt_i="27424" txt_f="27426">31</offsets></xref><offsets xml_i="38428" xml_f="38735" txt_i="27426" txt_f="27733">]. If the mechanism of action of cetuximab is more clearly understood it can be applied more selectively and its therapeutic index will be enhanced. Treatment related primary and acquired chemo- radioresistance presents a significant hindrance for all current therapy regimes in pancreatic cancer patients [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="38767" xml_f="38769" txt_i="27733" txt_f="27735">23</offsets></xref><offsets xml_i="38776" xml_f="38777" txt_i="27735" txt_f="27736">,</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="38809" xml_f="38811" txt_i="27736" txt_f="27738">24</offsets></xref><offsets xml_i="38818" xml_f="38981" txt_i="27738" txt_f="27901">]. Multiple factors such as genetic instability of tumors and high inter- and intratumoral heterogeneity contributes to the hardly predictable therapy resistance [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="39013" xml_f="39015" txt_i="27901" txt_f="27903">22</offsets></xref><offsets xml_i="39022" xml_f="40057" txt_i="27903" txt_f="28938">]. To understand patterns of therapy response genome expression profiling and detection of genetic polymorphisms enables to identify key mechanisms in systems biology. Microarray technology will be used to identify predictors for therapy response or failure. The objectives are to correlate and potentially predict therapy response to cetuximab in combination with gemcitabine and radiotherapy using tumor genomic fingerprints. Tissue will be obtained either prior to neoadjuvant therapy by biopsy or during surgery. In order to perform the genomic approach patients biopsies are correlated and RNA and DNA isolation will be performed. After expression profiling the most promising differentially expressed genes are validated using real-time quantitative polymerase chain reaction. To predict the efficacy of neoadjuvant trimodal therapy additionally patients blood is collected before, during, and after neoadjuvant therapy to detect and correlate well known tumor and angiogenesis marker (VEGF, bFGF, IL8 etc.) using antibody chips.</offsets></p></sec><sec><title><offsets xml_i="40079" xml_f="40132" txt_i="28940" txt_f="28993">Statistical considerations and sample size estimation</offsets></title><p><offsets xml_i="40143" xml_f="40462" txt_i="28994" txt_f="29313">The primary endpoint in this study is the feasibility and safety of the trimodal combination therapy with gemcitabine based chemoradiation and cetuximab. Secondary endpoints are overall survival period, measured from the date of therapy start. The one-year survival rates after chemoradiation with gemcitabine is 42 % [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="40494" xml_f="40496" txt_i="29313" txt_f="29315">20</offsets></xref><offsets xml_i="40503" xml_f="40504" txt_i="29315" txt_f="29316">,</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="40536" xml_f="40538" txt_i="29316" txt_f="29318">37</offsets></xref><offsets xml_i="40545" xml_f="40682" txt_i="29318" txt_f="29455">]. The sample size calculation is based on the assumption of an increase of one-year survival rates up to 67% due to the triple therapy [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="40714" xml_f="40716" txt_i="29455" txt_f="29457">30</offsets></xref><offsets xml_i="40723" xml_f="40724" txt_i="29457" txt_f="29458">-</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="40756" xml_f="40758" txt_i="29458" txt_f="29460">32</offsets></xref><offsets xml_i="40765" xml_f="40767" txt_i="29460" txt_f="29462">].</offsets></p><p><offsets xml_i="40774" xml_f="41176" txt_i="29463" txt_f="29865">Assuming an accrual period of 24 months and a follow-up of 42 months, testing for a difference in hazard (hazard ratio ≠ 1) on level α = 0.05 and with a power of 80% a study sample size of 58 patients (29 patients per study arm) is needed. Taking into consideration the estimate of approximately 15% of patients which will not complete the treatment, a total number of 66 patients should be randomized.</offsets></p><p><offsets xml_i="41183" xml_f="41422" txt_i="29866" txt_f="30105">The overall survival between both therapy arms will be compared using the Chi-square test. The overall survival will be summarized by Kaplan-Meier estimate and differences in therapy protocols will be analyzed by univariate Cox-regression.</offsets></p><p><offsets xml_i="41429" xml_f="41690" txt_i="30106" txt_f="30367">Various secondary endpoints will be evaluated in this study as well, time to progression, measured from date of therapy start, will be summarized by Kaplan-Meier estimate. Further tumor response after 3, and 6 months and secondary operability will be calculated</offsets></p><p><offsets xml_i="41697" xml_f="41867" txt_i="30368" txt_f="30538">One year after inclusion of the first patient an interim analysis will be carried out. The main evaluation will be performed two years after the last patient's enrolment.</offsets></p><p><offsets xml_i="41874" xml_f="42109" txt_i="30539" txt_f="30774">There will be explicit stopping rules in place to terminate the trial early in the unlikely event that an unacceptably high rate of treatment related deaths (TRD) is observed. TRD will be monitored using the design of Thall and Simon [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="42141" xml_f="42143" txt_i="30774" txt_f="30776">38</offsets></xref><offsets xml_i="42150" xml_f="42502" txt_i="30776" txt_f="31128">]. A non-informative Beta prior distribution (i.e., B (0.015, 0.085) for TRD rate is assumed. The trial will be stopped if at any point during the trial there is a greater than 90% probability that the true TRD rate is greater than 0.05. Each patient will subsequently be evaluated and, an independent safety board will be consulted in making decision.</offsets></p><p><offsets xml_i="42509" xml_f="43156" txt_i="31129" txt_f="31776">In view of the poor prognosis of the patient group, there will be no explicit stopping rules based on the overall number of toxicities, since even high rates of reversible toxicities seem acceptable if there is a large survival gain. Patients can withdraw from study participation at any time. Patients are taken off the study if unacceptable toxicity appears. Unacceptable toxicity is defined as unexpected serious side effects or irreversible Grade 4 toxicity. Patients who withdraw from the study may be treated with 5-FU and folinic acid or with gemcitabine. The decision will be based on the individual reasons for withdrawing from the study.</offsets></p></sec></sec><sec><title><offsets xml_i="43184" xml_f="43194" txt_i="31779" txt_f="31789">Discussion</offsets></title><p><offsets xml_i="43205" xml_f="43315" txt_i="31790" txt_f="31900">About 20–40% of patients present with a locally advanced pancreatic cancer which is not curable by resection [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="43346" xml_f="43347" txt_i="31900" txt_f="31901">3</offsets></xref><offsets xml_i="43354" xml_f="43355" txt_i="31901" txt_f="31902">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="43386" xml_f="43387" txt_i="31902" txt_f="31903">4</offsets></xref><offsets xml_i="43394" xml_f="43819" txt_i="31903" txt_f="32328">]. The aim of primary chemoradiation in this situation is to achieve a local response with the aim prolonged survival and of preventing local tumor complications. Further downstaging or downsizing may enable secondary respectability. Chemoradiation in locally advanced pancreatic cancer results in significantly prolonged survival with 1-year survival about 40% compared to chemotherapy alone with 1-year survival about 20% [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="43851" xml_f="43853" txt_i="32328" txt_f="32330">37</offsets></xref><offsets xml_i="43860" xml_f="44022" txt_i="32330" txt_f="32492">]. Long-term survival is poor, rarely do such patients achieve a complete response to treatment; median survival is 5–10 months and 5-year survival is near zero [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="44053" xml_f="44054" txt_i="32492" txt_f="32493">7</offsets></xref><offsets xml_i="44061" xml_f="44063" txt_i="32493" txt_f="32495">].</offsets></p><p><offsets xml_i="44070" xml_f="44291" txt_i="32496" txt_f="32717">Advantages in surgical techniques, radiation therapy techniques, chemotherapeutic regimes, and different combined-modality approaches have yielded only a modest impact on the prognosis of patients with pancreatic cancer [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="44322" xml_f="44323" txt_i="32717" txt_f="32718">4</offsets></xref><offsets xml_i="44330" xml_f="44937" txt_i="32718" txt_f="33325">]. Thus there is clearly a need for additional strategies. One approach involves using the identification of a number of molecular targets that may be responsible for the resistance of cancer cells to radiation or to other cytotoxic agents. As such, these molecular determinants may serve as targets for augmentation of the radiotherapy or chemotherapy response. Of these, the epidermal growth factor receptor (EGFR) has been a molecular target of considerable interest and investigation, and there has been a tremendous surge of interest in pursuing targeted therapy of cancers via inhibition of the EGFR [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="44969" xml_f="44971" txt_i="33325" txt_f="33327">23</offsets></xref><offsets xml_i="44978" xml_f="44979" txt_i="33327" txt_f="33328">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="45011" xml_f="45013" txt_i="33328" txt_f="33330">36</offsets></xref><offsets xml_i="45020" xml_f="45022" txt_i="33330" txt_f="33332">].</offsets></p><p><offsets xml_i="45029" xml_f="45287" txt_i="33333" txt_f="33591">Regarding the benefits of EGFR-targeted therapy in the combined modality treatment using either irradiation or chemotherapy, it is increasingly becoming clear that EGFR-targeted therapy is an important novel strategy for the treatment of pancreatic cancers [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="45319" xml_f="45321" txt_i="33591" txt_f="33593">30</offsets></xref><offsets xml_i="45328" xml_f="45329" txt_i="33593" txt_f="33594">-</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="45361" xml_f="45363" txt_i="33594" txt_f="33596">32</offsets></xref><offsets xml_i="45370" xml_f="45674" txt_i="33596" txt_f="33900">]. Since chemoradiation is the standard of care for locally advanced non metastatic pancreatic cancer, there has been considerable interest in gaining increased experience with this therapy in combination with chemoradiation in an effort to evaluate the efficacy and the toxicity profile of this regimen.</offsets></p><p><offsets xml_i="45681" xml_f="45802" txt_i="33901" txt_f="34022">Being a center focusing on pancreatic diseases and especially malignancies we therefore planned and conduct such a trial.</offsets></p><p><offsets xml_i="45809" xml_f="46334" txt_i="34023" txt_f="34548">The PARC study is an open, randomized controlled trial investigating the survival of patients with primary non-metastatic locally advanced pancreatic cancer after trimodal therapy with gemcitabine-based chemoradiation and EGFR-targeting therapy with the monoclonal antibody cetuximab. The role and the mechanism of cetuximab in patient's chemoradiation regimen are evaluated. The toxicity, the disease-free interval and the quality of life are assessed. Different factors are tested for a potential role as predictive marker.</offsets></p><p><offsets xml_i="46341" xml_f="46492" txt_i="34549" txt_f="34700">The results of the PARC trial will definitely advance clinical and scientific knowledge on the treatment of locally advanced pancreatic adenocarcinoma.</offsets></p></sec><sec><title><offsets xml_i="46514" xml_f="46527" txt_i="34702" txt_f="34715">Abbreviations</offsets></title><p><offsets xml_i="46538" xml_f="46572" txt_i="34716" txt_f="34750">CRO Clinical Research Organisation</offsets></p><p><offsets xml_i="46579" xml_f="46599" txt_i="34751" txt_f="34771">CRF Case Report Form</offsets></p><p><offsets xml_i="46606" xml_f="46634" txt_i="34772" txt_f="34800">CTC Common Toxicity Criteria</offsets></p><p><offsets xml_i="46641" xml_f="46667" txt_i="34801" txt_f="34827">CTV Clinical Target Volume</offsets></p><p><offsets xml_i="46674" xml_f="46708" txt_i="34828" txt_f="34862">dkfz German Cancer Research Center</offsets></p><p><offsets xml_i="46715" xml_f="46751" txt_i="34863" txt_f="34899">EBRT External Beam Radiation Therapy</offsets></p><p><offsets xml_i="46758" xml_f="46795" txt_i="34900" txt_f="34937">EGFR Epidermal Growth Factor Receptor</offsets></p><p><offsets xml_i="46802" xml_f="46828" txt_i="34938" txt_f="34964">GCP Good Clinical Practice</offsets></p><p><offsets xml_i="46835" xml_f="46858" txt_i="34965" txt_f="34988">GTV Gross Target Volume</offsets></p><p><offsets xml_i="46865" xml_f="46907" txt_i="34989" txt_f="35031">IMRT Intensity Modulated Radiation Therapy</offsets></p><p><offsets xml_i="46914" xml_f="46952" txt_i="35032" txt_f="35070">IORT Intra-Operative Radiation Therapy</offsets></p></sec><sec><title><offsets xml_i="46974" xml_f="46993" txt_i="35072" txt_f="35091">Competing interests</offsets></title><p><offsets xml_i="47004" xml_f="47064" txt_i="35092" txt_f="35152">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="47086" xml_f="47108" txt_i="35154" txt_f="35176">Authors' contributions</offsets></title><p><offsets xml_i="47119" xml_f="47647" txt_i="35177" txt_f="35705">The first two authors contributed equally. RK, MWM, SH, MWB and JD planned, coordinated and conducted the study. Medical care is covered by CT, BD, PB, KKH, and AA. RK, MWM, KKH and HF recruited patients and provided randomization. SN, CT, BD, PB, and AA took part in conducting the study. Scientific program is planned by RK and MWM and carried out by RK, MWM, PEH, AA and HF. SN provided technical assistance and quality control in radiation treatment planning and delivery. All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="47669" xml_f="47692" txt_i="35707" txt_f="35730">Pre-publication history</offsets></title><p><offsets xml_i="47703" xml_f="47767" txt_i="35731" txt_f="35795">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/131/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Trial medication (Cetuximab) is supplied by Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>FI</given-names></name><name><surname>Devesa</surname><given-names>SS</given-names></name></person-group><article-title>Cancer burden in the year 2000. The global Picture</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><fpage>S4</fpage><lpage>S66</lpage><pub-id pub-id-type="pmid">11602373</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(01)00267-2</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Samuels</surname><given-names>A</given-names></name><name><surname>Tiwari</surname><given-names>RC</given-names></name><name><surname>Ghafoor</surname><given-names>A</given-names></name><name><surname>Feuer</surname><given-names>EJ</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer statistics, 2005</article-title><source>CA Cancer J Clin</source><year>2005</year><volume>55</volume><fpage>10</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15661684</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Redaelli</surname><given-names>C</given-names></name><name><surname>Lietz</surname><given-names>M</given-names></name><name><surname>Seiler</surname><given-names>CA</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name></person-group><article-title>Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma</article-title><source>Br J Surg</source><year>2004</year><volume>91</volume><fpage>586</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15122610</pub-id><pub-id pub-id-type="doi">10.1002/bjs.4484</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beger</surname><given-names>HG</given-names></name><name><surname>Rau</surname><given-names>B</given-names></name><name><surname>Gansauge</surname><given-names>F</given-names></name><name><surname>Poch</surname><given-names>B</given-names></name><name><surname>Link</surname><given-names>KH</given-names></name></person-group><article-title>Treatment of pancreatic cancer: challenge of the facts</article-title><source>World J Surg</source><year>2003</year><volume>27</volume><fpage>1075</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">12925907</pub-id><pub-id pub-id-type="doi">10.1007/s00268-003-7165-7</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neoptolemos</surname><given-names>JP</given-names></name><name><surname>Stocken</surname><given-names>DD</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Dunn</surname><given-names>JA</given-names></name><name><surname>Hickey</surname><given-names>H</given-names></name><name><surname>Beger</surname><given-names>H</given-names></name><name><surname>Fernandez-Cruz</surname><given-names>L</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name><name><surname>Lacaine</surname><given-names>F</given-names></name><name><surname>Falconi</surname><given-names>M</given-names></name><name><surname>Pederzoli</surname><given-names>P</given-names></name><name><surname>Pap</surname><given-names>A</given-names></name><name><surname>Spooner</surname><given-names>D</given-names></name><name><surname>Kerr</surname><given-names>DJ</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name></person-group><article-title>European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>1200</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15028824</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa032295</pub-id></citation></ref><ref id="B6"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>D</given-names></name></person-group><article-title>Table 33</article-title><source>4-2, Principles and Practices of Oncology</source><year>2000</year><edition>6</edition><publisher-name>Lippincott, Williams, Wilkins, Inc</publisher-name><fpage>1130</fpage></citation></ref><ref id="B7"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>D</given-names></name></person-group><article-title>Table 33</article-title><source>4–8, Principles and Practices of Oncology</source><year>2000</year><edition>6</edition><publisher-name>Lippincott, Williams, Wilkins, Inc</publisher-name><fpage>1145</fpage></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalser</surname><given-names>MH</given-names></name><name><surname>Ellenberg</surname><given-names>SS</given-names></name></person-group><article-title>Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection</article-title><source>Arch Surg</source><year>1985</year><volume>120</volume><fpage>899</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">4015380</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><collab>Gastrointestinal Tumor Study Group</collab></person-group><article-title>Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer</article-title><source>Cancer</source><year>1987</year><volume>59</volume><fpage>2006</fpage><lpage>2010</lpage><pub-id pub-id-type="pmid">3567862</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klinkenbijl</surname><given-names>JH</given-names></name><name><surname>Jeekel</surname><given-names>J</given-names></name><name><surname>Sahmoud</surname><given-names>T</given-names></name><name><surname>van Pel</surname><given-names>R</given-names></name><name><surname>Couvreur</surname><given-names>ML</given-names></name><name><surname>Veenhof</surname><given-names>CH</given-names></name><name><surname>Arnaud</surname><given-names>JP</given-names></name><name><surname>Gonzalez</surname><given-names>DG</given-names></name><name><surname>de Wit</surname><given-names>LT</given-names></name><name><surname>Hennipman</surname><given-names>A</given-names></name><name><surname>Wils</surname><given-names>J</given-names></name></person-group><article-title>Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group</article-title><source>Ann Surg</source><year>1999</year><volume>230</volume><fpage>776</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">10615932</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199912000-00006</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stocken</surname><given-names>DD</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Jeekel</surname><given-names>H</given-names></name><name><surname>Klinkenbijl</surname><given-names>JH</given-names></name><name><surname>Bakkevold</surname><given-names>KE</given-names></name><name><surname>Takada</surname><given-names>T</given-names></name><name><surname>Amano</surname><given-names>H</given-names></name><name><surname>Neoptolemos</surname><given-names>JP</given-names></name><collab>Pancreatic Cancer Meta-analysis Group</collab></person-group><article-title>Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer</article-title><source>Br J Cancer</source><volume>92</volume><fpage>1372</fpage><lpage>81</lpage><comment>2005 Apr 25</comment><pub-id pub-id-type="pmid">15812554</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6602513</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spitz</surname><given-names>FR</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Pisters</surname><given-names>PW</given-names></name><name><surname>Lowy</surname><given-names>AM</given-names></name><name><surname>Fenoglio</surname><given-names>CJ</given-names></name><name><surname>Cleary</surname><given-names>KR</given-names></name><name><surname>Janjan</surname><given-names>NA</given-names></name><name><surname>Goswitz</surname><given-names>MS</given-names></name><name><surname>Rich</surname><given-names>TA</given-names></name><name><surname>Evans</surname><given-names>DB</given-names></name></person-group><article-title>Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>928</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">9060530</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>CH</given-names></name><name><surname>Beddar</surname><given-names>AS</given-names></name><name><surname>Evans</surname><given-names>DB</given-names></name></person-group><article-title>The role of intraoperative radiotherapy in pancreatic cancer</article-title><source>Surg Oncol Clin N Am</source><year>2003</year><volume>12</volume><fpage>965</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">14989127</pub-id><pub-id pub-id-type="doi">10.1016/S1055-3207(03)00090-5</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinsella</surname><given-names>TJ</given-names></name><name><surname>Sindelar</surname><given-names>WF</given-names></name></person-group><article-title>Intraoperative radiotherapy for pancreatic carcinoma. Experimental and clinical studies</article-title><source>Cancer</source><year>1996</year><volume>78</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">8681298</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emami</surname><given-names>B</given-names></name><name><surname>Lyman</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Coia</surname><given-names>L</given-names></name><name><surname>Goitein</surname><given-names>M</given-names></name><name><surname>Munzenrider</surname><given-names>JE</given-names></name><name><surname>Shank</surname><given-names>B</given-names></name><name><surname>Solin</surname><given-names>LJ</given-names></name><name><surname>Wesson</surname><given-names>M</given-names></name></person-group><article-title>Tolerance of normal tissue to therapeutic irradiation</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1991</year><volume>21</volume><fpage>109</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">2032882</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>MT</given-names></name><name><surname>Spector</surname><given-names>MH</given-names></name><name><surname>Ladman</surname><given-names>AJ</given-names></name></person-group><article-title>Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function</article-title><source>Cancer Treat Rev</source><year>1979</year><volume>6</volume><fpage>141</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">394833</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>JC</given-names></name><name><surname>Yang</surname><given-names>GY</given-names></name><name><surname>Ting</surname><given-names>JY</given-names></name><name><surname>Staley</surname><given-names>CA</given-names></name><name><surname>Torres</surname><given-names>W</given-names></name><name><surname>Esiashvili</surname><given-names>N</given-names></name><name><surname>Davis</surname><given-names>LW</given-names></name></person-group><article-title>Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity</article-title><source>Med Dosim</source><year>2002</year><volume>27</volume><fpage>121</fpage><lpage>9</lpage><comment>Summer</comment><pub-id pub-id-type="pmid">12074463</pub-id><pub-id pub-id-type="doi">10.1016/S0958-3947(02)00094-8</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>JY</given-names></name><name><surname>Iannitti</surname><given-names>DA</given-names></name><name><surname>Safran</surname><given-names>H</given-names></name></person-group><article-title>Combined modality therapy for pancreatic cancer</article-title><source>Semin Oncol</source><year>2003</year><volume>30</volume><fpage>71</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12908138</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawes</surname><given-names>RH</given-names></name><name><surname>Xiong</surname><given-names>Q</given-names></name><name><surname>Waxman</surname><given-names>I</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><name><surname>Evans</surname><given-names>DB</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name></person-group><article-title>A multispecialty approach to the diagnosis and management of pancreatic cancer</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><fpage>17</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10638554</pub-id><pub-id pub-id-type="doi"></pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Modiano</surname><given-names>MR</given-names></name><name><surname>Cripps</surname><given-names>MC</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Storniolo</surname><given-names>AM</given-names></name><name><surname>Tarassoff</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>R</given-names></name><name><surname>Dorr</surname><given-names>FA</given-names></name><name><surname>Stephens</surname><given-names>CD</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name></person-group><article-title>Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>2403</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">9196156</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name></person-group><article-title>Update on combined-modality treatment options for pancreatic cancer</article-title><source>Oncology (Huntingt)</source><year>2003</year><volume>17</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">14723004</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>TS</given-names></name></person-group><article-title>Radiation sensitizers and targeted therapies</article-title><source>Oncology (Huntingt)</source><year>2003</year><volume>17</volume><fpage>23</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14723003</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>M</given-names></name><name><surname>Krause</surname><given-names>M</given-names></name></person-group><article-title>Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results</article-title><source>Radiother Oncol</source><year>2004</year><volume>72</volume><fpage>257</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">15450723</pub-id><pub-id pub-id-type="doi">10.1016/j.radonc.2004.07.007</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>HQ</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name></person-group><article-title>Epidermal growth factor receptor-targeted therapy for pancreatic cancer</article-title><source>Semin Oncol</source><year>2002</year><volume>29</volume><fpage>31</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12422311</pub-id><pub-id pub-id-type="doi">10.1053/sonc.2002.35645</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowers</surname><given-names>G</given-names></name><name><surname>Reardon</surname><given-names>D</given-names></name><name><surname>Hewitt</surname><given-names>T</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Mikkelsen</surname><given-names>RB</given-names></name><name><surname>Valerie</surname><given-names>K</given-names></name><name><surname>Lammering</surname><given-names>G</given-names></name><name><surname>Amir</surname><given-names>C</given-names></name><name><surname>Schmidt-Ullrich</surname><given-names>RK</given-names></name></person-group><article-title>The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells</article-title><source>Oncogene</source><volume>20</volume><fpage>1388</fpage><lpage>97</lpage><comment>2001 Mar 15</comment><pub-id pub-id-type="pmid">11313882</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1204255</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt-Ullrich</surname><given-names>RK</given-names></name><name><surname>Mikkelsen</surname><given-names>RB</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Todd</surname><given-names>DG</given-names></name><name><surname>Valerie</surname><given-names>K</given-names></name><name><surname>Kavanagh</surname><given-names>BD</given-names></name><name><surname>Contessa</surname><given-names>JN</given-names></name><name><surname>Rorrer</surname><given-names>WK</given-names></name><name><surname>Chen</surname><given-names>PB</given-names></name></person-group><article-title>Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation</article-title><source>Oncogene</source><volume>15</volume><fpage>1191</fpage><lpage>7</lpage><comment>1997 Sep 4</comment><pub-id pub-id-type="pmid">9294612</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1201275</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Harari</surname><given-names>PM</given-names></name></person-group><article-title>Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>2166</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">10873065</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harari</surname><given-names>PM</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name></person-group><article-title>Modulation of molecular targets to enhance radiation</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>323</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10690506</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>ES</given-names></name><name><surname>Khuri</surname><given-names>FR</given-names></name><name><surname>Herbst</surname><given-names>RS</given-names></name></person-group><article-title>Epidermal growth factor receptor biology (IMC-C225)</article-title><source>Curr Opin Oncol</source><year>2001</year><volume>13</volume><fpage>506</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11673692</pub-id><pub-id pub-id-type="doi">10.1097/00001622-200111000-00014</pub-id></citation></ref><ref id="B30"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Bonner</surname><given-names>JA</given-names></name><name><surname>Harari</surname><given-names>PM</given-names></name><name><surname>Giralt</surname><given-names>JL</given-names></name></person-group><article-title>Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of the head and neck: a phase III study of high dose radiation therapy with or without cetuximab</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><comment>abstract 5507</comment></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>HQ</given-names></name><name><surname>Rosenberg</surname><given-names>A</given-names></name><name><surname>LoBuglio</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>W</given-names></name><name><surname>Wolff</surname><given-names>RA</given-names></name><name><surname>Deutsch</surname><given-names>J</given-names></name><name><surname>Needle</surname><given-names>M</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name></person-group><article-title>Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial</article-title><source>J Clin Oncol</source><volume>22</volume><fpage>2610</fpage><lpage>6</lpage><comment>2004 Jul 1</comment><pub-id pub-id-type="pmid">15226328</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2004.12.040</pub-id></citation></ref><ref id="B32"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Hamm</surname><given-names>J</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Hecht</surname><given-names>J</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Au</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><name><surname>Christy-Bittel</surname><given-names>J</given-names></name><name><surname>Parulekar</surname><given-names>W</given-names></name></person-group><article-title>Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] ASCO Meeting Abstracts</article-title><year>2005</year><volume>23</volume><fpage>1</fpage></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Duez</surname><given-names>NJ</given-names></name><name><surname>Filiberti</surname><given-names>A</given-names></name><name><surname>Flechtner</surname><given-names>H</given-names></name><name><surname>Fleishman</surname><given-names>SB</given-names></name><name><surname>de Haes</surname><given-names>JC</given-names></name><etal></etal></person-group><article-title>The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><fpage>365</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8433390</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hjermstad</surname><given-names>MJ</given-names></name><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Kaasa</surname><given-names>S</given-names></name></person-group><article-title>Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>1249</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">7738629</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzsimmons</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>CD</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>Sandberg</surname><given-names>AA</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Beger</surname><given-names>HG</given-names></name><name><surname>Birk</surname><given-names>D</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name><name><surname>Fernandez Cruz</surname><given-names>L</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Grahm</surname><given-names>AL</given-names></name><name><surname>Jeekel</surname><given-names>J</given-names></name><name><surname>Laugier</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Singer</surname><given-names>MW</given-names></name><name><surname>Tihanyi</surname><given-names>T</given-names></name></person-group><article-title>Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer EORTC Study Group on Quality of Life</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>939</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10533475</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(99)00047-7</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>HQ</given-names></name></person-group><article-title>Molecular targeting therapy for pancreatic cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2004</year><volume>54</volume><fpage>S69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">15316751</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><article-title>Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group</article-title><source>J Natl Cancer Inst</source><volume>80</volume><fpage>751</fpage><lpage>5</lpage><comment>1988 Jul 20</comment><pub-id pub-id-type="pmid">2898536</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thall</surname><given-names>PF</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>Practical Bayesian guidelines for phase IIB clinical trials</article-title><source>Biometrics</source><year>1994</year><volume>50</volume><fpage>337</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">7980801</pub-id></citation></ref></ref-list></back></article>